Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 172 clinical trials
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer

) after melphalan conditioning regimen in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) or does not respond to treatment (refractory). The

bevacizumab
measurable disease
carcinoma
ny-eso-1
cancer
  • 12 views
  • 25 Jan, 2021
  • 1 location
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen

This study is an extension to younger patients of the currently ongoing national, multicenter, open-label, randomized phase III HAPLOMUDELDERLY which evaluates elderly patients with hematological malignancies, justifying an allo-HSCT from an alternative donor when a MRD has not been identified. It will extend the investigation of these two modalities of …

hematologic malignancy
cancer
cell transplantation
transplant conditioning
  • 1 views
  • 22 Jan, 2021
  • 1 location
Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies

This is a Phase II trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with alpha/beta T and CD19+ depleted peripheral stem cell grafts

shortening fraction
allogeneic hematopoietic stem cell transplant
transplant conditioning
histiocytosis
reduced intensity conditioning
  • 3 views
  • 24 Jan, 2021
  • 1 location
JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation

This is a Phase 1 study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in patients with

  • 0 views
  • 27 Jan, 2021
  • 6 locations
Clofarabine Pre-allogeneic Stem Cell Transplant for Non-remission AML

The Investigators would like to study the incidence of complete remission (CR) at day +30 after Clofarabine followed by haploidentical transplant. The conditioning regimen used is Fludarabine

colony stimulating factor
granulocyte colony stimulating factor
serum bilirubin level
remission
clofarabine
  • 0 views
  • 27 Jan, 2021
  • 1 location
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with

myeloproliferative disorder
myelodysplastic syndromes
lymphoma
acute leukemia
chronic lymphocytic leukemia, relapsed
  • 0 views
  • 26 Jan, 2021
  • 1 location
Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

transplant with either a myeloablative or non-myeloablative conditioning regimen, and recipients of all donor sources will be enrolled to this trial.

  • 0 views
  • 31 Jan, 2021
  • 1 location
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

as a conditioning regimen for hematopoietic cell transplant. Phase II: The primary purpose of this study phase is to assess the complete response (CR) conversion rate.

cell transplantation
dexamethasone
transplant conditioning
chemotherapy regimen
melphalan
  • 0 views
  • 27 Jan, 2021
  • 1 location
Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases

The hypothesis of this study is that children with severe primary immunodeficiencies will benefit from early stem cell transplantation utilizing a reduced intensity conditioning regimen

  • 8 views
  • 07 Nov, 2020
  • 1 location
Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

cell transplantation (allo-HSCT) adding gemcitabine to the standard institutional conditioning regimen based on two alkylating drugs, reduced busulfan and cyclophosphamide (reduced BUCY 2).

  • 1 views
  • 24 Jan, 2021
  • 1 location